OR WAIT null SECS
© 2023 MJH Life Sciences™ and BioPharm International. All rights reserved.
Catalent expands gene therapy capabilities with $1.2-billion acquisition of Paragon Bioservices.
Catalent, Inc. announced on May 20, 2019 the completion of a $1.2-billion acquisition of Paragon Bioservices, Inc., a viral vector development and manufacturing company for gene therapies with expertise in adeno-associated virus vectors. Paragon’s capabilities will enhance Catalent’s biologics business and integrated biopharmaceutical solutions for customers, Catalent reported in a press statement announcing the close of the sale.
Paragon is working on GMP manufacturing projects with more than half of the top 40 leading gene therapy developers worldwide, according to the statement. The company recently opened a commercial manufacturing center near the Baltimore-Washington International airport, which is equipped with several 500-L and 2000-L single-use bioreactors for clinical through commercial material production. The production campus-combined with a leased second building that will be built out for commercial GMP manufacturing-has the potential for more than 425,000-sq.ft. of manufacturing space upon completion, Catalent reports.
Source: Catalent Pharma Solutions